Caribou Biosciences plans a substantial workforce reduction as it stops development of its two allogeneic CAR-T therapy programs and begins a review of strategic alternatives.
Foghorn Therapeutics plans to cut about 40% of its workforce, leaving about 65 full-time employees, after it and Eli Lilly decided not to advance FHD-909 into the expansion phase, according to an Oct. 1 SEC filing.
AstraZeneca said it is investing more than $1 billion in Massachusetts, which will expand its workforce in the state by more than 50% in the coming years, as it opened a new global R&D centre in Kendall Square.
